1,570 Amgen Inc. $AMGN Shares Purchased by Versant Capital Management Inc

Versant Capital Management Inc raised its stake in Amgen Inc. (NASDAQ:AMGN) by 79.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,550 shares of the medical research company’s stock after purchasing an additional 1,570 shares during the period. Versant Capital Management Inc’s holdings in Amgen were worth $1,496,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Wellington Altus USA Inc. boosted its holdings in shares of Amgen by 72.3% during the 2nd quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock worth $28,000 after buying an additional 34 shares during the period. Tower View Wealth Management LLC grew its stake in Amgen by 331.6% in the 1st quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after buying an additional 63 shares during the last quarter. Security National Bank of Sioux City Iowa IA bought a new position in Amgen in the 2nd quarter valued at about $36,000. Evergreen Advisors LLC bought a new position in Amgen in the 1st quarter valued at about $37,000. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in Amgen during the fourth quarter worth approximately $44,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $407.27 on Friday. Amgen Inc. has a 12-month low of $288.00 and a 12-month high of $447.03. The company’s 50 day moving average price is $410.18 and its two-hundred day moving average price is $370.10. The firm has a market cap of $220.18 billion, a PE ratio of 25.31, a PEG ratio of 3.04 and a beta of 0.41. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the business earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts predict that Amgen Inc. will post 22.94 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were issued a $2.52 dividend. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.5%. Amgen’s payout ratio is currently 62.65%.

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Rachna Khosla sold 2,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,222 shares of company stock valued at $2,540,926 over the last ninety days. Insiders own 0.85% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AMGN. Piper Sandler boosted their price objective on Amgen from $427.00 to $457.00 and gave the stock an “overweight” rating in a report on Thursday, August 20th. HSBC lowered Amgen from a “buy” rating to a “hold” rating and lowered their target price for the stock from $445.00 to $425.00 in a research note on Thursday, September 10th. Citigroup boosted their price target on Amgen from $345.00 to $405.00 and gave the company a “neutral” rating in a research note on Friday, August 7th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $410.00 price objective on shares of Amgen in a report on Wednesday, September 23rd. Finally, Canaccord Genuity Group upped their price objective on Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average target price of $385.25.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.